Cargando…
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
Two doses of the MVA-CoV2-S vaccine candidate expressing the SARS-CoV-2 spike (S) protein protected K18-hACE2 transgenic mice from a lethal dose of SARS-CoV-2. This vaccination regimen prevented virus replication in the lungs, reduced lung pathology, and diminished levels of pro-inflammatory cytokin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828760/ https://www.ncbi.nlm.nih.gov/pubmed/35140227 http://dx.doi.org/10.1038/s41541-022-00440-w |
_version_ | 1784647914020143104 |
---|---|
author | Lázaro-Frías, Adrián Pérez, Patricia Zamora, Carmen Sánchez-Cordón, Pedro J. Guzmán, María Luczkowiak, Joanna Delgado, Rafael Casasnovas, José M. Esteban, Mariano García-Arriaza, Juan |
author_facet | Lázaro-Frías, Adrián Pérez, Patricia Zamora, Carmen Sánchez-Cordón, Pedro J. Guzmán, María Luczkowiak, Joanna Delgado, Rafael Casasnovas, José M. Esteban, Mariano García-Arriaza, Juan |
author_sort | Lázaro-Frías, Adrián |
collection | PubMed |
description | Two doses of the MVA-CoV2-S vaccine candidate expressing the SARS-CoV-2 spike (S) protein protected K18-hACE2 transgenic mice from a lethal dose of SARS-CoV-2. This vaccination regimen prevented virus replication in the lungs, reduced lung pathology, and diminished levels of pro-inflammatory cytokines. High titers of IgG antibodies against S and receptor-binding domain (RBD) proteins and of neutralizing antibodies were induced against parental virus and variants of concern, markers that correlated with protection. Similar SARS-CoV-2-specific antibody responses were observed at prechallenge and postchallenge in the two-dose regimen, while the single-dose treatment does not avoid vaccine breakthrough infection. All vaccinated animals survived infection and were also protected to SARS-CoV-2 reinfection. Furthermore, two MVA-CoV2-S doses induced long-term memory S-specific humoral and cellular immune responses in C57BL/6 mice, 6 months after immunization. The efficacy and immunological benefits of the MVA-CoV2-S vaccine candidate against COVID-19 supports its consideration for human clinical trials. |
format | Online Article Text |
id | pubmed-8828760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88287602022-02-24 Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice Lázaro-Frías, Adrián Pérez, Patricia Zamora, Carmen Sánchez-Cordón, Pedro J. Guzmán, María Luczkowiak, Joanna Delgado, Rafael Casasnovas, José M. Esteban, Mariano García-Arriaza, Juan NPJ Vaccines Article Two doses of the MVA-CoV2-S vaccine candidate expressing the SARS-CoV-2 spike (S) protein protected K18-hACE2 transgenic mice from a lethal dose of SARS-CoV-2. This vaccination regimen prevented virus replication in the lungs, reduced lung pathology, and diminished levels of pro-inflammatory cytokines. High titers of IgG antibodies against S and receptor-binding domain (RBD) proteins and of neutralizing antibodies were induced against parental virus and variants of concern, markers that correlated with protection. Similar SARS-CoV-2-specific antibody responses were observed at prechallenge and postchallenge in the two-dose regimen, while the single-dose treatment does not avoid vaccine breakthrough infection. All vaccinated animals survived infection and were also protected to SARS-CoV-2 reinfection. Furthermore, two MVA-CoV2-S doses induced long-term memory S-specific humoral and cellular immune responses in C57BL/6 mice, 6 months after immunization. The efficacy and immunological benefits of the MVA-CoV2-S vaccine candidate against COVID-19 supports its consideration for human clinical trials. Nature Publishing Group UK 2022-02-09 /pmc/articles/PMC8828760/ /pubmed/35140227 http://dx.doi.org/10.1038/s41541-022-00440-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lázaro-Frías, Adrián Pérez, Patricia Zamora, Carmen Sánchez-Cordón, Pedro J. Guzmán, María Luczkowiak, Joanna Delgado, Rafael Casasnovas, José M. Esteban, Mariano García-Arriaza, Juan Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice |
title | Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice |
title_full | Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice |
title_fullStr | Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice |
title_full_unstemmed | Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice |
title_short | Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice |
title_sort | full efficacy and long-term immunogenicity induced by the sars-cov-2 vaccine candidate mva-cov2-s in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828760/ https://www.ncbi.nlm.nih.gov/pubmed/35140227 http://dx.doi.org/10.1038/s41541-022-00440-w |
work_keys_str_mv | AT lazarofriasadrian fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT perezpatricia fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT zamoracarmen fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT sanchezcordonpedroj fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT guzmanmaria fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT luczkowiakjoanna fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT delgadorafael fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT casasnovasjosem fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT estebanmariano fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice AT garciaarriazajuan fullefficacyandlongtermimmunogenicityinducedbythesarscov2vaccinecandidatemvacov2sinmice |